{"filings":[{"id":778876,"accession_number":"0001213900-26-063531","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-06-01T20:30:19+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports Phase 1 combo data: 24% ORR, 33% in endometrial cancer; Phase 2 planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of LYMPHIR + pembrolizumab in 25 heavily pre-treated gynecologic cancer patients showed 24% ORR (5 partial responses); median duration of response not reached.","In endometrial cancer patients previously treated with checkpoint inhibitors, ORR was 33%; one response ongoing >3 years.","48% of 21 evaluable patients achieved clinical benefit; median PFS among that group was 20.5 months.","Safety manageable: only one Gr 3 CLS at highest dose; no new safety signals or Gr 3+ immune-related AEs.","A Phase 2 expansion study is being planned to further evaluate the combo in gynecologic cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472000,"accession_number":"0001213900-26-057876","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-05-15T20:41:12+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma Q2 2026: $5.6M H1 LYMPHIR revenue, 80% gross margins; raises $36.5M at Citius Oncology","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue $1.7M in Q2 (launch quarter); $5.6M in H1 2026 vs. zero a year ago.","Payer coverage near 100% of commercial lives; 83% of target accounts on formulary or in review.","Citius Oncology secured up to $36.5M debt/equity; Citius Pharma raised $5M direct offering.","Net loss $21.2M in Q2 ($0.95/share) vs. $10.9M a year ago; includes $19.7M CMO cancellation charge.","First LYMPHIR shipment to Europe via Uniphar; positive Phase 1 combo data with pembrolizumab and pre-CAR-T."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":5611409.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93265,"accession_number":"0001213900-26-053916","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma subsidiary amends $3.8M note, adds conversion at $0.90, subordinates to senior debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Third Amendment to Promissory Note dated May 4, 2026, between Citius Oncology and Citius Pharmaceuticals.","Entire unpaid principal balance of $3.8M now due 91 days after senior debt fully paid and loan agreement terminated.","Prior maturity triggers from capital raises, debt/equity issuance, or royalty monetization eliminated.","New voluntary conversion feature allows parent to convert principal into shares at $0.90 per share, subject to subsidiary approval.","Note subordinated to Avenue Venture Opportunities Fund's senior debt; cash prepayment prohibited before new maturity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93264,"accession_number":"0001213900-26-049338","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["3.02","1.01","8.01","9.01"],"status":"ready","headline":"Citius Oncology ships first international order of LYMPHIR to Europe","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First international shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe through a regional distribution partner.","Product will be available via Named Patient Programs under applicable local regulations.","LYMPHIR approved by FDA in August 2024 for relapsed/refractory CTCL; U.S. commercial launch in December 2025.","Citius Oncology (Nasdaq: CTOR) is a majority-owned subsidiary of Citius Pharmaceuticals (CTXR).","International expansion complements ongoing U.S. launch progress with formulary access and payer coverage."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93263,"accession_number":"0001213900-26-047599","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma raises $5M via registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 5,076,143 shares/pre-funded warrants at $0.985 each; raised ~$5M gross, $4.5M net.","Issued unregistered warrants to purchase 5,076,143 shares at $0.86, 5-year term, cashless exercise.","Net proceeds to fund commercial launch of LYMPHIR and development of product candidates.","45-day lock-up on further equity issuance after closing; H.C. Wainwright acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93262,"accession_number":"0001213900-26-040474","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Citius shareholders elect seven directors, ratify auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected: Mazur, Holubiak, Dutia, Holuka, McGrath, Smith, Webb.","Broker non-votes of ~6.66M shares on each director; no broker non-votes on auditor ratification.","Ratification of Wolf & Company as auditor: 8,593,946 for, 855,866 against, 673,867 abstain.","Directors serve one-year term expiring at 2027 annual meeting or until successors qualified."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104741,"accession_number":"0001213900-26-037524","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Oncology reports early LYMPHIR launch momentum with 83% of target accounts in formulary review","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["83% of target accounts have added or are actively progressing LYMPHIR through formulary review.","~135 health plans, covering ~80% of covered lives, secured; no reimbursement denials reported.","Repeat orders from early accounts; initial penetration into community infusion centers underway.","Investigator-sponsored studies: positive topline data in DLBCL at ASTCT 2026; Phase I combo with pembrolizumab completed.","International expansion underway via distribution agreements in Europe and Middle East."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104740,"accession_number":"0001213900-26-025459","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-03-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharmaceuticals reports positive Phase 1 topline results for LYMPHIR/pembrolizumab combo in gynecologic cancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1 trial of LYMPHIR plus KEYTRUDA in 25 evaluable patients with relapsed/refractory gynecologic cancers showed 24% objective response rate and 48% clinical benefit rate.","No unexpected safety signals or serious immune-related adverse events were observed at any dose level in the University of Pittsburgh-led study.","Full safety and efficacy results expected to be presented at an international cancer conference later this year.","Study investigators highlight potential for LYMPHIR to augment immune checkpoint inhibitor efficacy in ovarian cancer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104739,"accession_number":"0001213900-26-023439","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius subsidiary reports Phase 1 data: LYMPHIR + CAR-T shows 86% ORR, 57% CR in high-risk DLBCL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORR 86% at 1 month (57% CR, 29% PR) in 14 patients with relapsed/refractory DLBCL.","One-year PFS 77% (95% CI: 43–92%); one-year OS 84% (95% CI: 49–96%).","Well-tolerated: no dose-limiting toxicities, no Grade≥3 LYMPHIR-related immune AEs.","Single LYMPHIR dose depleted circulating Tregs (median reduction 24 Tregs/µL).","Study conducted at Univ of Minnesota and City of Hope; presented at 2026 Tandem Meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104738,"accession_number":"0001213900-26-015895","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["2.02","3.01","9.01"],"status":"ready","headline":"Citius Pharma posts first revenue of $3.9M from LYMPHIR launch; Nasdaq warns of bid price deficiency","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 FY2026 revenue $3.9M from initial LYMPHIR sales; net loss $8.2M ($0.41 loss per share).","Cash and equivalents $7.7M; raised ~$20.9M from equity financings in quarter.","Nasdaq notified company of bid price deficiency; has until Aug 10, 2026 to regain compliance.","LYMPHIR launched Dec 2025; early physician adoption; international patient access via Named Patient Programs.","Late-stage pipeline includes Mino-Lok and Halo-Lido; engaging with FDA on next steps."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":3944111.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121024,"accession_number":"0001213900-25-125413","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma reports FY2025 net loss $39.7M; launches LYMPHIR in December 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.7M ($3.38/share) vs $40.2M ($5.97/share) prior year; no revenue.","R&D expenses $9.2M vs $11.9M YoY; G&A $18.5M vs $18.2M YoY.","Raised ~$61M in gross proceeds: $25M at Citius Pharma, $36M at Citius Oncology (CTOR).","LYMPHIR launched in U.S. December 2025 for CTCL; secured NCCN Category 2A and HCPCS J-code.","Cash and equivalents $4.3M at Sep 30, 2025; continued FDA engagement on Mino-Lok and Halo-Lido."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121023,"accession_number":"0001213900-25-116760","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Citius Oncology launches LYMPHIR for CTCL; first marketed product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR (denileukin diftitox-cxdl) now commercially available in U.S. for relapsed/refractory Stage I–III CTCL after prior systemic therapy.","Phase 3 pivotal study: ORR 36.2%, 84% skin tumor burden reduction, median response time 1.4 months, no cumulative toxicity.","Estimated U.S. market >$400M; permanent J-code (J9161) effective April 1, 2025; NCCN Category 2A recommendation.","International expansion via Integris Pharma distribution agreement for Southern Europe and Balkan countries.","Patient assistance program (Citius Advantage) and HCP portal (lymphirhcp.com) launched to support access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121022,"accession_number":"0001213900-25-101741","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Citius Pharmaceuticals updates corporate presentation; reiterates LYMPHIR Q4 2025 launch and pipeline progress","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["LYMPHIR (denileukin diftitox-cxdl) FDA approved for CTCL; commercial launch planned Q4 2025.","Mino-Lok Phase 3 completed with positive topline data meeting primary and secondary endpoints.","Halo-Lido Phase 2b completed; only prescription therapy under development for hemorrhoids.","Citius Oncology (CTOR) spun off August 2024; CTXR intends to distribute CTOR shares to CTXR shareholders.","Over $90M invested in LYMPHIR; new J-code (J9161) and NCCN guidelines inclusion secured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121021,"accession_number":"0001213900-25-100847","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharmaceuticals raises $6.0M in registered direct offering for LYMPHIR launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$6.0M; net ~$5.5M after placement agent fees and expenses.","Offering: 3,973,510 shares/pre-funded warrants plus 3,973,510 common warrants at $1.51/share.","Common warrants exercisable at $1.40/share, 5-year term; pre-funded warrants at $0.0001/share.","Net proceeds to support commercial launch of LYMPHIR™ and other product candidates.","H.C. Wainwright acted as placement agent; 7.0% cash fee and 278,146 placement agent warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137641,"accession_number":"0001213900-25-075034","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma Q3 fiscal 2025 net loss narrows to $9.2M; LYMPHIR launch on track for Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.2M ($0.80 per share) vs $10.6M ($1.57 per share) in the prior-year quarter.","Cash and equivalents $6.1M at June 30; raised $12.5M in gross financings during the quarter.","LYMPHIR launch for cutaneous T-cell lymphoma planned Q4 2025; manufacturing and distribution agreements in place.","Citius Oncology raised additional $9M in July 2025 to fund pre-launch activities.","Mino-Lok discussions with FDA continue; evaluating best path forward for antibiotic lock solution."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":137640,"accession_number":"0001213900-25-062099","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius regains compliance with Nasdaq minimum bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq confirmed compliance with Listing Rule 5550(a)(2) after 10 consecutive trading days with bid price at $1.00 or greater.","Compliance period from June 20, 2025 to July 3, 2025; previously scheduled hearing panel cancelled.","CTXR common stock will continue to be listed and traded on Nasdaq Capital Market.","Chairman and CEO Leonard Mazur stated the company remains focused on critical care products and shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155012,"accession_number":"0001213900-25-053607","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma closes $6M registered direct offering with warrants for up to $9.8M additional proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $6M from sale of 4.92M shares/pre-funded warrants at $1.22 per share.","Short-term warrants to purchase up to 9.84M shares at $1.00; expire 24 months from issuance.","Net proceeds ~$5.455M after fees; used for LYMPHIR commercial launch and corporate purposes.","H.C. Wainwright placement agent; 7% cash fee plus placement agent warrants at $1.525 exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155011,"accession_number":"0001213900-25-052718","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Citius Pharmaceuticals increases authorized shares 10x, redeems Series A Preferred for $100","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized shares increased from 26M to 260M; common shares from 16M to 250M.","Amendment approved at special meeting on June 9, 2025: 547M for, 457M against, 520K abstain.","Series A Preferred (1B votes) automatically redeemed for $100, mirrored votes cast proportionally.","Adjournment proposal became moot after amendment approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155010,"accession_number":"0001213900-25-050822","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Citius Pharma issues $1M unsecured note at 15% interest; CEO personally guarantees","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$1M principal unsecured promissory note issued to Pagoda Resources on June 2, 2025.","Interest rate 15% per year, compounded monthly; mature date December 2, 2025.","Company may prepay at any time without penalty; note non-convertible.","CEO Leonard Mazur provides unconditional personal guaranty of full repayment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155009,"accession_number":"0001213900-25-049550","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Citius Pharma receives Nasdaq delisting notice for bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 29, 2025 for failing minimum $1 bid price for 33 consecutive business days.","Not eligible for compliance period due to reverse stock split within prior year.","Plans to appeal by June 5, 2025 to stay suspension; delisting would start June 9 without appeal.","No assurance that Nasdaq will grant relief or that compliance can be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155008,"accession_number":"0001213900-25-043362","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.","Cash and cash equivalents only $26,410 as of March 31, 2025.","Company will need additional capital to support operations beyond May 2025.","R&D expenses $3.8M; G&A expenses $4.8M, both up vs prior year.","Plans to secure financing for LYMPHIR launch; retained Jefferies for strategic alternatives."],"consensus_eps_estimate":-0.6018,"consensus_eps_actual":-2.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155007,"accession_number":"0001213900-25-033366","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","9.01"],"status":"ready","headline":"Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.","Board amended bylaws reducing stockholder meeting quorum from majority to one-third to avoid adjournment risk.","Series A has no conversion, dividend, or liquidation rights; redeemed for $100 automatically after vote results announced.","Special meeting called; preliminary proxy filed for shareholder vote on the authorized share increase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155006,"accession_number":"0001213900-25-028622","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-04-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Oncology amends license agreement with Eisai, defers $8.2M in LYMPHIR payments to 2025","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Total obligations owed to Eisai: $8,233,209.77 including $5.9M milestone and $2.33M development/inventory costs.","Payment schedule: $2,535,317.77 by July 15, 2025; four monthly $2.35M payments; final $2,197,892.07 by Dec 15, 2025.","Interest at 2% per annum on delayed amounts from original due dates.","Parties released each other from claims related to late payment of milestone and other costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155005,"accession_number":"0001213900-25-028003","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma raises $2M in registered direct offering; proceeds for LYMPHIR launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 465,000 shares at $1.15 and 1,274,131 pre-funded warrants at $1.1499.","Net proceeds ~$1.735M after fees; used for commercial launch of LYMPHIR and general corporate purposes.","Placement agent H.C. Wainwright received 7% cash fee and 121,739 warrants exercisable at $1.4375.","Company agreed to 30-day lock-up on further equity issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173524,"accession_number":"0001213900-25-022237","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Citius shareholders defeat share-increase proposal, elect all director nominees","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal to raise authorized shares from 26M to 260M failed with 3,222,490 for vs. 1,934,414 against.","All seven director nominees elected; Leonard Mazur received 2,301,986 for, 983,591 withheld.","Advisory vote on executive compensation approved: 1,943,011 for, 1,196,649 against, 1,969,380 broker non-votes.","Ratification of Wolf & Co. as auditor for FY2025 passed with 4,466,905 for, 592,161 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173523,"accession_number":"0001213900-25-014359","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-02-14T23:59:59+00:00","items":["8.01","2.02","9.01"],"status":"ready","headline":"Citius Pharma Q1 2025 net loss $10.3M; prepares LYMPHIR launch H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.3M ($1.30 per share) vs. $9.2M ($1.45) in Q1 2024; cash $1.1M as of Dec 31, 2024.","G&A expenses rose to $5.4M on pre-launch LYMPHIR activities; R&D fell to $2.1M as trials completed.","LYMPHIR received permanent J-code (J9161) effective April 1, 2025; launch expected in first half 2025.","Citius Oncology engaged Jefferies to evaluate strategic alternatives; raised $6.5M in equity placements.","Nasdaq compliance regained after 1-for-25 reverse stock split in November 2024."],"consensus_eps_estimate":-0.391,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173522,"accession_number":"0001213900-25-010747","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharma receives permanent J-code J9161 for LYMPHIR, effective April 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS assigned permanent HCPCS J-code J9161 to LYMPHIR (denileukin diftitox-cxdl) for CTCL.","J-code effective April 1, 2025, streamlines billing and reimbursement for providers.","LYMPHIR approved by FDA for relapsed/refractory Stage I-III CTCL after prior systemic therapy.","CEO Leonard Mazur says J-code is critical for patient access and coverage by commercial & government insurers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173521,"accession_number":"0001213900-25-002071","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma raises ~$3M in registered direct offering of stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 743,496 shares plus warrants for 743,496 shares at combined price of $4.035 per unit.","Warrants exercisable at $4.035/share (8-K) or $3.91/share (press release), expire in 5 years.","Net proceeds ~$2.7M after fees; intended for clinical development and working capital.","H.C. Wainwright placement agent with 7% cash fee, $50k legal, $35k expense, and 52,045 placement agent warrants at $5.0438.","Offering closed January 8, 2025 under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173520,"accession_number":"0001213900-25-001408","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2025-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharma reports LYMPHIR launch prep progress; targeting H1 2025 commercial launch","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LYMPHIR approved Aug 2024 for relapsed/refractory CTCL; commercial launch targeted H1 2025.","Secured commercial supply agreements with CMOs; first-year launch supply already produced.","Submitted J-code application under HCPCS; secured inclusion in NCCN guidelines.","Designing patient assistance program and building specialized sales team for CTCL providers.","Exploring international licensing partnerships and expanded indications, including combination immunotherapy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190511,"accession_number":"0001213900-24-113158","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma reports FY 2024 net loss of $39.4M; FDA approval of LYMPHIR highlights","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.4M ($5.97/share) for FY ended Sep 30, 2024 vs $32.5M ($5.57) prior year.","Cash & equivalents $3.3M; plans to raise additional capital.","R&D expense $11.9M, G&A $18.2M; stock-based compensation $11.8M.","FDA approved LYMPHIR (denileukin diftitox-cxdl) for CTCL; commercial launch expected H1 2025.","Completed Citius Oncology spin-off (CTOR) on Nasdaq in August 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190510,"accession_number":"0001213900-24-111212","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Citius Pharmaceuticals regains Nasdaq compliance on bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 18, 2024 confirming compliance with Listing Rule 5550(a)(2).","Stock closed at $1.00 or more for 12 consecutive trading days from Nov 26 to Dec 12, 2024.","Nasdaq stated the matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190509,"accession_number":"0001213900-24-102833","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Citius Pharmaceuticals effects 1-for-25 reverse stock split to regain Nasdaq bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25 ratio effective Nov 25, 2024; split-adjusted trading begins Nov 26.","Authorized shares reduced from 400M to 16M; issued shares from ~193M to ~7.7M.","No fractional shares issued; fractional interests rounded up to nearest whole share.","Intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.","Trading symbol remains CTXR; new CUSIP 17322U306."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190508,"accession_number":"0001213900-24-102265","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharmaceuticals Reports Productive FDA Type C Meeting for Mino-Lok Phase 3 Program","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Citius Pharma held a constructive in-person Type C meeting with the FDA on November 25, 2024, regarding its Phase 3 Mino-Lok trial for catheter-related bloodstream infections.","The FDA provided clear, actionable guidance on clinical efficacy and safety data, supporting a pathway to a future New Drug Application (NDA) submission.","Chairman and CEO Leonard Mazur stated the Agency's comprehensive feedback provides a strong framework for completing remaining steps toward an NDA.","Mino-Lok, if approved, could reduce healthcare costs and improve outcomes by salvaging central venous catheters instead of removing them."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190507,"accession_number":"0001213900-24-099649","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma raises $3M in registered direct offering of 12M shares and 12M warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering consists of 12M common shares and warrants for 12M shares at combined $0.25; gross proceeds $3.0M.","Net proceeds approx. $2.7M after fees; intended for R&D, working capital, and general corporate purposes.","Warrants exercisable at $0.25 per share, immediately exercisable, expire in 5 years; cashless exercise if no effective registration.","Placement agent H.C. Wainwright receives 7% cash fee plus 840,000 placement agent warrants at $0.3125 per share.","Closing occurred November 18, 2024; offering made under existing effective shelf registration (File No. 333-277319)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190506,"accession_number":"0001213900-24-097495","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq panel grants Citius Pharma extension to regain bid price compliance by Dec 3, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company received bid price deficiency notice on Sep 12, 2023, extended to Sep 9, 2024.","After failing to regain compliance, hearing requested and held on Oct 29, 2024.","Panel decision on Nov 6, 2024 grants continued listing subject to compliance deadline Dec 3, 2024.","Company must provide prompt notification of any significant events affecting compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190505,"accession_number":"0001213900-24-096268","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius reports 27% ORR in Phase I trial of pembrolizumab + LYMPHIR for recurrent solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27% objective response rate (4/15) and 33% clinical benefit rate; median PFS 57 weeks for patients with clinical benefit.","Trial enrolled 21 patients; three more to enroll before Phase I portion completes.","Combination well-tolerated; only one DLT (capillary leak syndrome) at 12 mcg/kg; no serious immune-related AEs.","Two of four partial responders had prior anti-PD-1 therapy, suggesting potential in checkpoint-resistant patients.","Phase II expansion planned across broader solid tumor types including gynecologic and other histologies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207007,"accession_number":"0001213900-24-082809","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-09-27T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Citius extends employment agreement with EVP Holubiak and insider warrants to 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Myron Holubiak's employment term extended by one year to Oct 31, 2025; all other terms unchanged.","Investor warrants for 2,793,297 shares at $0.77 held by CEO Mazur and EVP Holubiak extended to Sept 27, 2025.","Underwriter warrants for 194,358 shares at $1.11875 extended to same date, held by Wainwright representatives.","Full exercise of all extended warrants would yield ~$2.4M in cash proceeds to the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207006,"accession_number":"0001213900-24-078288","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Citius Pharma obtains partial deferral of milestone payment to Dr. Reddy's under LYMPHIR deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Reddy's agreed to partial deferral without penalty of a milestone payment due Sep 9, 2024.","Milestone was triggered by FDA approval of LYMPHIR under the 2021 Asset Purchase Agreement.","Payment is by Citius Oncology, Inc.; Citius Pharmaceuticals, Inc. remains guarantor.","All other terms and conditions of the Asset Purchase Agreement remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207005,"accession_number":"0001213900-24-077777","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Citius Pharma receives Nasdaq delisting determination for bid price non-compliance; plans hearing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received delisting determination on Sept 10, 2024 after failing to regain $1.00 bid price compliance by extended deadline of Sept 9, 2024.","Company will request hearing before Nasdaq Hearing Panel, which automatically stays suspension/delisting pending outcome.","Panel may grant additional extension of up to 180 days from delisting letter date to regain compliance.","No assurance that relief or continued listing will be granted. Stock trades on Nasdaq Capital Market under CTXR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207004,"accession_number":"0001213900-24-076108","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"LYMPHIR added to NCCN Guidelines for CTCL treatment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NCCN Category 2A recommendation supports LYMPHIR as option for relapsed/refractory CTCL after at least one prior systemic therapy.","LYMPHIR targets IL-2 receptor on malignant T-cells; FDA approved based on Phase 3 study results.","CEO says NCCN inclusion could aid physician adoption and ease reimbursement, potentially expanding CMS coverage.","Citius Pharma (CTXR) and Citius Oncology (CTOR) jointly announced the guideline addition on Sep 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207003,"accession_number":"0001213900-24-070285","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Citius Pharma completes SPAC merger, forms Citius Oncology; holds ~90% of new public company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger closed Aug 12, 2024; Citius Oncology expected to trade on Nasdaq as CTOR on Aug 13.","Citius Pharma owns approximately 90% of Citius Oncology after the merger.","LYMPHIR (denileukin diftitox) approved by FDA for relapsed/refractory cutaneous T-cell lymphoma.","Citius Pharma made $3.8M capital contribution to Citius Oncology via no-interest promissory note.","Amended shared services and registration rights agreements executed; shares subject to 6-month lock-up."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207002,"accession_number":"0001213900-24-067778","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma Q3 net loss $10.6M; FDA approves LYMPHIR, oncology spin-off begins trading","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA approved LYMPHIR (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma on Aug 12, 2024.","Oncology subsidiary merged with TenX Keane; Citius Oncology (Nasdaq: CTOR) starts trading Aug 13, 2024.","Mino-Lok Phase 3 trial met primary and secondary endpoints; cash $17.9M as of June 30, 2024, with runway through Dec 2024.","Net loss $10.6M ($0.06/sh) for Q3 ended June 30, 2024, vs $8.5M ($0.06/sh) a year ago; R&D expenses $2.8M."],"consensus_eps_estimate":-0.4964,"consensus_eps_actual":-4.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207001,"accession_number":"0001213900-24-066357","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharma receives FDA approval for LYMPHIR (denileukin diftitox-cxdl) in r/r CTCL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Phase 3 study showed 36.2% ORR, 8.7% complete response, median time to response 1.41 months.","First FDA-approved product for Citius; launch expected within next five months.","Boxed warning for capillary leak syndrome; postmarketing requirement to assess visual impairment risk.","Only systemic therapy targeting IL-2 receptor on malignant T-cells and Tregs for CTCL.","US market for r/r CTCL estimated at $300–$400 million; no cumulative toxicity observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224304,"accession_number":"0001213900-24-045573","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharma: Mino-Lok Phase 3 trial meets primary endpoint (p=0.0006) in CLABSI/CRBSI","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: time to catheter failure significantly delayed for Mino-Lok vs control (p=0.0006); hazard ratio 0.53.","Median time-to-failure for control arm: 33 days; Mino-Lok arm median not reached (NE; CI 50 days-NE).","Secondary endpoint overall success: 57.1% Mino-Lok vs 37.7% control (p=0.0025).","No drug-related serious adverse events reported; safety profile supports well-tolerated designation.","Company plans to engage with FDA to determine next regulatory steps for Mino-Lok."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224303,"accession_number":"0001213900-24-042966","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Citius Pharma Q2 net loss $8.5M; LYMPHIR PDUFA Aug 13, Mino-Lok data due Q2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $12.6M at Mar 31; $15M April offering extends runway through Dec 2024.","LYMPHIR BLA accepted with PDUFA target date August 13, 2024.","Mino-Lok Phase 3 topline results anticipated in calendar Q2 2024.","Merger of oncology sub with TenX (TENK) progressing; pending SEC/TENK approval.","Net loss $8.5M ($0.05/shr) vs $10.5M loss a year ago; R&D expense down."],"consensus_eps_estimate":-0.6018,"consensus_eps_actual":-2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224302,"accession_number":"0001213900-24-037861","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Citius Pharma raises ~$15M in registered direct offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 21.43M shares and warrants to buy 21.43M shares at $0.70/combined unit.","Warrants exercisable at $0.75/share from 6 months after issuance, expire in 5 years.","Gross proceeds ~$15M; net proceeds ~$13.8M after placement agent fees and expenses.","Proceeds for general corporate purposes, including pre-clinical/clinical development and working capital.","Offering closed April 30, 2024; H.C. Wainwright acted as exclusive placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224301,"accession_number":"0001213900-24-030829","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-04-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Citius extends CEO/EVP warrants to April 5, 2025; exercise would yield $2.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved one-year extension for 1,294,498 Investor Warrants held by CEO Leonard Mazur and EVP Myron Holubiak, exercise price $1.42 each.","Also extended 240,130 Placement Agent Warrants held by H.C. Wainwright representatives, exercise price $1.9313 per share.","Warrants were originally issued in April 2019 and previously extended to April 2024; no other warrants from that offering remain.","Full exercise of all extended warrants would generate about $2.3 million in cash proceeds for the company.","All other terms and conditions of the warrants remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243645,"accession_number":"0001213900-24-023483","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-03-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Citius Pharma: FDA accepts BLA resubmission for LYMPHIR (CTCL); PDUFA Aug 13, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted BLA resubmission for LYMPHIR (denileukin diftitox) to treat relapsed/refractory cutaneous T-cell lymphoma.","PDUFA target action date set for August 13, 2024.","Resubmission addresses July 2023 CRL; no safety or efficacy issues cited, no additional trials required.","BLA supported by pivotal Phase 3 study (NCT01871727)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":243644,"accession_number":"0001213900-24-022184","cik":1506251,"company_name":"Citius Pharmaceuticals, Inc.","ticker":"CTXR","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["3.01","5.07"],"status":"ready","headline":"Citius Pharma gets Nasdaq bid-price compliance extension to Sept 9, 2024; annual meeting elects directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq granted extension until Sept 9, 2024 to regain $1.00 minimum bid price; stock continues trading under CTXR.","If compliance not achieved by Sept 9, 2024, Nasdaq will issue delisting notice; company can appeal to hearings panel.","At March 12 annual meeting, all seven director nominees elected (Leonard Mazur, Myron Holubiak, Suren Dutia, Dr. Eugene Holuka, Dennis McGrath, Robert Smith, Carol Webb).","Stockholders ratified Wolf & Company as auditor for FY ending Sept 30, 2024 with 77.2M votes for, 2.5M against.","Company evaluating options to regain bid price compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":18074771.801739134,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}